% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • hokiestock hokiestock Jan 23, 2013 10:29 PM Flag

    16 dollar price target

    Roth capital raised their target from 11 to 16 today. Sighting 011 future trials, 1127 clean tolerability profile, DDD drug, and did not even mention the Glio prospect which I think is the first one of the box and on base in a couple years. Buy and hold or buy in segements, I believe like most companies the big companies will probably make CLDX fund most into phase 3 and then try to come in for a kill.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Agree that 16 is a base case scenario and only is considers we get a reasonable SPA agreement with FDA for phase III for CDX-011 starting phase III by end of the year. It doesn't in my opinion include any surprise upside potential or partnership announcements or conditional approval of CDX-011 for use in triple negative patients during phase III or a buy out that would certainly double this 1 year target. I'm increasing my recommendation from BUY to STRONG BUY with a target of $32 on probability that one or more of the surprise upside catalysts occur this year. te he

      Sentiment: Strong Buy

4.04+0.24(+6.32%)Sep 30 4:00 PMEDT